Table 1.
Patient Characteristics
| HFpEF | HFpEF, no fatigue | Diastolic dysfunction | |||||||
|---|---|---|---|---|---|---|---|---|---|
| No (n=52) | Yes (n=37) | P value | No (n=59) | Yes (n=30) | P value | No (n=42) | Yes (n=47) | P value | |
| Age (mean, SD) | 49.0 (9.7) | 52.4 (8.7) | 0.10 | 48.9 (9.5) | 53.6 (8.4) | 0.02 | 48.6 (9.3) | 52.1 (9.3) | 0.08 |
| Women (n, %) | 22 (42.3) | 16 (43.2) | 1 | 24 (40.7) | 14 (46.7) | 0.75 | 17 (40.5) | 21 (44.7) | 0.85 |
| White race (n, %) | 46 (88.5) | 36 (97.3) | 0.13 | 53 (89.8) | 29 (96.7) | 0.26 | 36 (85.7) | 46 (97.9) | 0.03 |
| BMI (mean, SD) | 35.5 (6.4) | 37.5 (7.6) | 0.18 | 35.4 (6.7) | 38.3 (7.2) | 0.07 | 35.9 (6.5) | 36.8 (7.4) | 0.53 |
| Diabetes (n, %) | 21 (40.4) | 11 (29.7) | 0.42 | 24 (40.7) | 8 (26.7) | 0.29 | 17 (40.5) | 15 (31.9) | 0.54 |
| Hypertension (n, %) | 36 (69.2) | 31 (83.8) | 0.19 | 42 (71.2) | 25 (83.3) | 0.32 | 28 (66.7) | 39 (83.0) | 0.13 |
| Total cholesterol (mean, SD) | 181.6 (45.5) | 187.7 (44.6) | 0.55 | 186.5 (46.9) | 179.7 (41.2) | 0.53 | 187.8 (43.6) | 181.1 (46.3) | 0.52 |
| LDL (mean, SD) | 113.27 (39.2) | 108.56 (39.2) | 0.61 | 114.04 (38.4) | 105.64 (40.5) | 0.38 | 118.56 (38.5) | 104.95 (38.8) | 0.13 |
| HDL (mean, SD) | 37.4 (9.2) | 38.5 (18.5) | 0.71 | 38.9 (15.4) | 35.6 (9.3) | 0.32 | 37.7 (9.0) | 37.9 (17.0) | 0.95 |
| Statin prescribed (n, %) | 11 (21.2) | 18 (48.6) | 0.006 | 15 (25.4) | 14 (46.7) | 0.04 | 8 (19.0) | 21 (44.7) | 0.01 |
| Fibrosis stage (n, %) | 0.14 | 0.45 | 0.08 | ||||||
| Stage 0 | 0 (0.0) | 3 (8.1) | 1 (1.7) | 2 (6.7) | 0 (0.0) | 3 (6.4) | |||
| Stage 1 | 9 (17.3) | 7 (18.9) | 10 (16.9) | 6 (20.0) | 6 (14.3) | 10 (21.3) | |||
| Stage 2 | 24 (46.2) | 15 (40.5) | 25 (42.4) | 14 (46.7) | 17 (40.5) | 22 (46.8) | |||
| Stage 3 | 18 (34.6) | 9 (24.3) | 21 (35.6) | 6 (20.0) | 18 (42.9) | 9 (19.1) | |||
| Stage 4 | 1 (1.9) | 3 (8.1) | 2 (3.4) | 2 (6.7) | 1 (2.4) | 3 (6.4) | |||
BMI indicates body mass index; HDL, high‐density lipoprotein; and LDL, low‐density lipoprotein.